23 Furthermore, a study conducted using synthetic peptides also implied that the N-terminus could be a Co2+-binding site on HSA.24 Bar-Or et al. proposed that HSA from myocardial ischemia patients may possess N-terminal modifications resulting in lower Co2+ binding.12 Based on this hypothesis, the ACB assay was developed,25 which was later approved by the FDA. The gene discussed is ALB; the disease is myocardial ischemia.